Mongolia vs Suriname: Access to anti-retroviral drugs, male
Mongolia
42.0%
in 2024
Suriname
41.0%
in 2024
Mongolia rank
128th
Suriname rank
130th
Access to anti-retroviral drugs, male over time
- Mongolia
- Suriname
How they compare
Mongolia currently reports 42.0% against 41.0% in Suriname, a difference of 1.0%.
The two have swapped places 7 times across 25 shared years of data; in 2000 it was Suriname ahead.
Mongolia ranks 128th and Suriname ranks 130th of 141 countries.
Across the 3 decades both report, Mongolia averaged higher in 1 and Suriname in 2.
Head to head by decade
| Decade | Mongolia | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.7% | 5.6% | 4.9% | Suriname |
| 2010s | 22.9% | 25.2% | 2.3% | Suriname |
| 2020s | 38.8% | 37.6% | 1.2% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Mongolia or Suriname?
- Mongolia, at 42.0% against 41.0% in Suriname as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Mongolia and Suriname?
- 1.0%, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Suriname?
- 25 years are reported by both, from 2000 to 2024.
- How do Mongolia and Suriname rank globally for access to anti-retroviral drugs, male?
- Mongolia ranks 128th and Suriname ranks 130th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.